Ultragenyx's gene therapy helps control ammonia levels in late-stage study

Core Insights - Ultragenyx Pharmaceutical's experimental gene therapy, DTX301, has shown promising results in controlling ammonia levels in patients with ornithine transcarbamylase (OTC) deficiency, improving ammonia control by 18% after 36 weeks compared to a placebo [1][1][1] - The therapy was generally well tolerated, with the most common side effects being liver-related issues that were manageable with steroids [1][1][1] Company Summary - Ultragenyx Pharmaceutical is focused on developing gene therapies for rare inherited disorders, with DTX301 targeting OTC deficiency, a condition caused by the lack of a liver enzyme necessary for ammonia clearance [1][1][1] - The company reported that the therapy's effectiveness in managing ammonia levels could significantly impact the treatment landscape for patients suffering from this rare disorder [1][1][1]